Executive Summary
Publicis Groupe S.A. gains a stable $373.9M revenue stream via subsidiary Plowshare Group from a CDC tobacco education contract ending March 30, 2026, with $275.5M already outlayed signaling execution reliability. Unexercised options worth $123.9M offer upside, but fiscal uncertainties loom near term-end. This underscores persistent federal commitment to public health advertising amid potential budget pressures.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior High-Value Federal Grants ($5M+) digest from March 29, 2026.
Investment Signals (1)
- Publicis Groupe Locks in $374M CDC Contract Revenue (HIGH)▲
$373.9M obligated (potential $497.8M with options) under Time & Materials for tobacco campaign, with $275.5M outlayed providing multi-year stability through 2026.
Risk Flags (2)
- Market [MEDIUM RISK]▼
Funding cuts or renewal uncertainty as contract nears 2026-03-30 end.
- Execution [MEDIUM RISK]▼
Time & Materials structure exposes to government audits on hours/rates; only 74% of obligation outlayed.
Opportunities (1)
- ◆
Unexercised options add $123.9M potential; follow-on CDC tobacco campaigns post-2026.
Sector Themes (1)
- ◆
CDC's $374M+ commitment to tobacco education via ad agencies highlights sustained high-value contracts in health campaigns.
Watch List (1)
- 👁
{"entity"=>"Publicis Groupe S.A.", "reason"=>"Contract end-date aligns with period; $124M options and renewal potential drive near-term volatility.", "trigger"=>"Option exercises, outlay acceleration >$98M remaining, or HHS renewal notices"}
Get daily alerts with 1 investment signals, 2 risk alerts, 1 opportunities and full AI analysis of all 1 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: High-Value Federal Grants ($5M+)
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
S&P 500 Technology Sector SEC Filings — May 27, 2026
S&P 500 Technology Sector SEC Filings
May 27, 2026
Orphan Drug Approvals — May 27, 2026
Orphan Drug Approvals
May 27, 2026
Big Pharma Approvals — May 27, 2026
Big Pharma Approvals